ABSTRACT
OBJECTIVE： To analyze the formulation regularity of Chinese patent medicines containing Paeonia lactiflora， and to provide evidence for modern clinical application and R&D of P. lactiflora. METHODS： The formulations of Chinese patent medicine containing P. lactiflora were collected from Chinese Materia Medica Preparation and 2015 edition of Chinese Pharmacopeia. Statistical analysis was performed on the frequency of medicinal material， channel tropism， distribution of attending syndromes and attending diseases， core medicine combination （support degrees were set as 10％， 20％， 30％ and confidence degree was 0.9） by using data mining methods such as descriptive statistics and association rule analysis in TCM Inheritance System V 2.5； the formulation regularity of common attending syndromes and attending diseases （support degrees were set as 20％， 30％， 40％ and confidence degree was 0.9） was analyzed. RESULTS： A total of 600 Chinese patent medicine formulations contained P. lactiflora， involving 673 ingredients. The main medicinal properties in Chinese patent medicines containing P. lactiflora were warm， followed by cold and neutral. The main medicinal flavor was sweet， followed by bitter and pungent. The main channel tropism was spleen， liver and heart channel. There were 165 kinds of main treatment diseases （menstrual disorder， dysmenorrhea， dizziness） and 159 main treatment syndromes （insufficiency of qi and blood， qi stagnation and blood stasis， liver and kidney deficiency）. Under the condition of 30％ support degree and 0.9 confidence degree， there were 20 core combination of Chinese patent medicine formulations containing P. lactiflora （Glycyrrhiza uralensis-P. lactiflora， Angelica sinensis-P. lactiflora， P. lactiflora-Poria cocos） and 19 association rules among drugs. Under the condition of 40％ support degree and 0.9 confidence degree， there were 8 core medicines in Chinese patent medicines containing P. lactiflora for menstrual disorders （such as P. lactiflora， Cyperus rotundus， A. sinensis）， 9 core medicines for dizziness （such as P. lactiflora， Rehmannia glutinosa， A. sinensis）， 9 core medicines for qi and blood deficiency （such as P. lactiflora， Atractylodes macrocephala， P. cocos）， and 10 core medicines for qi stagnation and blood stasis syndrome （such as P. lactiflora， Aucklandia lappa， G. uralensis）. CONCLUSIONS： In this study， data mining was used to analysis the main symptoms， compatibility characteristics and formulation rules of Chinese patent medicines containing P. lactiflora， which can provide a basis for the modern clinical application and new drug development of P. lactiflora.
ABSTRACT
Objective: To observe the effect of Scolopendra subspinipes extracts (SSE) on signal transducer and activator of transcription 3 (STAT3) signaling pathway and phosphorylation of its protein expression as well as the regulation mechanisms of HepG2 cells proliferation, invasion, and metastasis after SSE exposure. Methods: HepG2 cells were processed with SSE of gradient concentration (300, 600, 1 200, and 2 400 μg/mL). The inhibitory effect of SSE on HepG2 cell proliferation was evaluated by CCK8 method. Subsequent experimental concentration was set from IC50 result of CCK8 methods. HepG2 cells were divided into control, SSE (250 and 500 μg/mL), and 5-FU groups. After HepG2 cells were treated with SSE for 48 h, Transwell Chambers detected the invasion of HepG2 cells and Western blotting demonstrated expression and activation of STAT3, p-STAT3 and VEGF, MMP-2 protein. Results: CCK8 method showed that SSE had obvious inhibition effect on human HepG2 cells proliferation with dose dependent effect (P < 0.05). The IC50 of SSE was 508.3 μg/mL at 48 h. Transwell result showed invasive ability of human HepG2 cells was significantly reduced compared with control group after SSE worked to cells for 48 h (P < 0.05). Compared with 250 μg/mL SSE group, the number of membrane cells in 500 μg/mL SSE and 5-FU groups were less (P < 0.05). Western blotting analysis showed that STAT3 signaling pathway was mainly down regulated by p-STAT3 expression after SSE worked to cells for 48 h. Compared with control group, the p-STAT3 expression of SSE was down-regulated (P < 0.05). The MMP-2 and VEGF protein expression of 500 μg/mL SSE decreased compared with control group (P < 0.05). The MMP-2 protein expression of 500 μg/mL SSE group had obvious difference compared with the 250 μg/mL SSE group (P < 0.05). Conclusion: SSE regulate the activation of human HepG2 cells STAT3 signaling pathway by STAT3 phosphorylation down-regulation and reduce the expression of MMP-2 and VEGF downstream target protein, thus inhibited HepG2 cells proliferation, invasion, and metastasis ability in vitro.
ABSTRACT
OBJECTIVE:To systematically review the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of the non-small cell lung cancer (NSCLC),and provide evidence-based reference for clinical treatment. METH-ODS:Retrieved from PubMed,Cochrane Library,EMBase,VIP,CJFD,Wanfang database and CBM,randomized controlled tri-als(RCT)about the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC were collect-ed. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with modified Jadad scale. RESULTS:Totally 9 RCTs were included,involving 561 patients. Results of Meta-analysis showed,Kanglaite injection com-bined with radiothreapy can significantly improve the effective rate [OR=2.99,95%CI(2.07,4.31),P<0.001] and improvement rate of life quality [OR=3.74,95%CI(2.36,5.92),P<0.001],and reduce the incidence of radiation pneumonitis [OR=0.23,95%CI (0.12,0.47),P<0.001] and radiation esophagitis [OR=0.10,95%CI(0.05,0.21),P<0.001] of NSCLC patients,the differences were statistically significant. CONCLUSIONS:Both the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC are superior to radiothreapy alone.
ABSTRACT
Objective To find new compound from gorgonian.Methods Three ceramides have been isolated from the South China Sea gorgonian Echinogorgia sp.by silica gel column chromatography.Results Their structures were established as(2S,3S,4R)-N-[2-(1,3,4-trihydroxyicosan-2-yl)]-hexadecanamide(1),(2S,3S,4R)-N-[2-(1,3,4-trihydroxyicosan-2-yl)]-heptadecanamide(2),and(2S,3S,4R)-N-[2-(1,3,4-trihydroxyicosan-2-yl]-octadecanamide(3) by spectroscopic methods and chemical conversion.Conclusion It is the first time to report the three chemical compounds from coral Echinogorgia sp.and compound 2 is a new compound.